Search Result "ATR checkpoint pathway"
Combining DNA Damaging Agents and Checkpoint 1 Inhibitors
Journal: Current Medicinal Chemistry - Anti-Cancer Agents
Volume: 4 Issue: 5 Year: 2004 Page: 435-438
Author(s): Michelle Prudhomme
Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy
Journal: Current Cancer Drug Targets
Volume: 16 Issue: 3 Year: 2016 Page: 200-208
Author(s): Martin Andrs,Jan Korabecny,Eugenie Nepovimova,Daniel Jun,Zdenek Hodny,Kamil Kuca
Novel Checkpoint 1 Inhibitors
Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 1 Issue: 1 Year: 2006 Page: 55-68
Author(s): Michelle Prudhomme
Current Inhibitors of Checkpoint Kinase 2
Journal: Current Medicinal Chemistry
Volume: 18 Issue: 2 Year: 2011 Page: 4368-4374
Author(s): T. N.T. Nguyen, J. J. Tepe
Modulation of DNA Damage Checkpoint; Patenting and Possible Application for Cancer Medicine
Journal: Recent Patents on DNA & Gene Sequences (DIscontinued)
Volume: 2 Issue: 1 Year: 2008 Page: 34-39
Author(s): Kazuhiro Ishikawa, Hideshi Ishii, Keiichi Ichimura
Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Journal: Current Medicinal Chemistry
Volume: 24 Issue: 1 Year: 2017 Page: 1504-1519
Author(s): Nicholas D`Arcy,Brian Gabrielli
DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment
Journal: Current Cancer Drug Targets
Volume: 12 Issue: 4 Year: 2012 Page: 356-371
Author(s): S. Solier,Y. -W. Zhang,A. Ballestrero,Y. Pommier,G. Zoppoli
Cell Cycle Checkpoint Genes and Aneuploidy: A Short Review
Journal: Current Genomics
Volume: 2 Issue: 2 Year: 2001 Page: 171-180
Author(s): William G. Kearns, Johnson M. Liu
New Insights into the Roles of XPA and RPA in DNA Repair and Damage Responses
Journal: Current Chemical Biology
Volume: 1 Issue: 2 Year: 2007 Page: 151-160
Author(s): Yiyong Liu, Yue Zou
Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Journal: Current Clinical Pharmacology
Volume: 5 Issue: 3 Year: 2010 Page: 186-191
Author(s): Suzanne Leijen, Jos H. Beijnen, Jan H.M. Schellens